Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Yale University

Status and phase: Terminated; Phase 2

Conditions: Chronic Lymphocytic Leukemia

Treatments: Drug: Maintenance lenalidomide

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01465230

1105008515

Details and patient eligibility

About

This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).

Enrollment: 2 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previous induction treatment with bendamustine and rituximab
• 18 or more years of age
• chronic lymphocytic leukemia
• ECOG performance status less than or equal to 2
• Absolute neutrophile count more than 1,000
• Platelet count more than 70,000

Exclusion criteria

• Serious medical condition that would prevent treatment with lenalidomide
• Evidence of tumor lysis syndrome
• Any prior treatment with lenalidomide

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

lenalidomide

Experimental group

Description:

Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.

Treatment:

Drug: Maintenance lenalidomide